Neutrophil/Lymphocyte (N/L) Ratio and Long Term Follow-up in ST-elevation Myocardial Infarction - Full Text View

Purpose

Although the pre-procedural neutrophil to lymphocyte ratio (N/L) has been associated with adverse outcomes among patients with coronary artery disease, its role during the acute phase of ST-segment elevation myocardial infarction (STEMI) has not been fully investigated. This study sought to investigate the association of the pre-procedural N/L ratio within-hospital and long-term outcomes among STEMI patients undergoing primary percutaneous coronary intervention (PCI).

Condition	Intervention
ST Elevated Myocardial Infarction	Procedure: primary percutaneous coronary intervention, each groups

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Observational Study of N/L Ratio in Patients With STEMI

Resource links provided by NLM:

MedlinePlus related topics: Heart Attack

U.S. FDA Resources

Further study details as provided by TC Erciyes University:

Biospecimen Retention: Samples Without DNA

serum and plasma of blood

Enrollment:	1034
Study Start Date:	January 2000
Study Completion Date:	July 2012
Primary Completion Date:	July 2012 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
N/L ratio tertile 2 patients were divided in to the tertiles	Procedure: primary percutaneous coronary intervention, each groups All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
N/L ratio tertile 3 patients were divided in to the tertiles	Procedure: primary percutaneous coronary intervention, each groups All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
N/L ratio tertile 1 patients were divided in to the tertiles	Procedure: primary percutaneous coronary intervention, each groups All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).

Detailed Description:

Inflammation plays a role in the initiation and progression of the atherosclerotic process. Due to a growing recognition of its role, recent studies have focused on inflammatory markers and their association with outcomes in patients with ST-segment elevation myocardial infarction (STEMI). Recently, our single center study demonstrated that preprocedural neutrophil/lymphocyte (N/L) ratio is an independent predictor of impaired coronary flow after primary percutaneous coronary intervention (PCI) and of in-hospital major advanced cardiac events (MACE) in patients with STEMI.Several previous studies also evaluated the role of N/L ratio in long-term outcomes among patients with STEMI; however, they evaluated the association between long-term mortality and in-hospital N/L ratio, they were single-center studies and they evaluated a relatively small study population.

In the present multicenter experience, the investigators aimed to investigate the association of the preprocedural N/L ratio with the in-hospital and long-term outcomes in patients with STEMI undergoing primary PCI.

Eligibility

Ages Eligible for Study:	18 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

STEMI patients who were admitted within 6 hours from symptom onset and who underwent primary PCI were prospectively included in this study

Criteria

Inclusion Criteria:

ST elevated myocardial infarction

Exclusion Criteria:

Treatment with fibrinolytic drugs in the previous 24 hours Active infection Previously documented history of a systemic inflammatory process Known malignancy End-stage liver disease Renal failure

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01663194

Locations

Turkey
Erciyes University school of medicine
Kayseri, Turkey, 38039

Sponsors and Collaborators

TC Erciyes University

Investigators

Study Director:

Mahmut Akpek, MD

Erciyes University school of medicine

More Information

No publications provided

Responsible Party:	Mahmut Akpek, Medical doctor of cardiology department, TC Erciyes University
ClinicalTrials.gov Identifier:	NCT01663194 History of Changes
Other Study ID Numbers:	mgkaya-makpek
Study First Received:	August 9, 2012
Last Updated:	August 13, 2012
Health Authority:	Turkey: Ethics Committee

Keywords provided by TC Erciyes University:

N/L ratio, STEMI, primary PCI, Long-term mortality

Additional relevant MeSH terms:

Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis

Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 23, 2013